97 related articles for article (PubMed ID: 34166727)
21. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
Wykosky J; Gibo DM; Debinski W
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3208-18. PubMed ID: 18089715
[TBL] [Abstract][Full Text] [Related]
22. EPH receptor A2 governs a feedback loop that activates Wnt/β-catenin signaling in gastric cancer.
Peng Q; Chen L; Wu W; Wang J; Zheng X; Chen Z; Jiang Q; Han J; Wei L; Wang L; Huang J; Ma J
Cell Death Dis; 2018 Nov; 9(12):1146. PubMed ID: 30451837
[TBL] [Abstract][Full Text] [Related]
23. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
[TBL] [Abstract][Full Text] [Related]
24. EphA2 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer cells.
Huang J; Xiao D; Li G; Ma J; Chen P; Yuan W; Hou F; Ge J; Zhong M; Tang Y; Xia X; Chen Z
Oncogene; 2014 May; 33(21):2737-47. PubMed ID: 23752181
[TBL] [Abstract][Full Text] [Related]
25. miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer.
Huang J; He Y; Mcleod HL; Xie Y; Xiao D; Hu H; Chen P; Shen L; Zeng S; Yin X; Ge J; Li L; Tang L; Ma J; Chen Z
BMC Cancer; 2017 Dec; 17(1):886. PubMed ID: 29273006
[TBL] [Abstract][Full Text] [Related]
26. Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy.
Ma R; Ma ZG; Gao JL; Tai Y; Li LJ; Zhu HB; Li L; Dong DL; Sun ZJ
J Biomed Mater Res A; 2020 Jan; 108(1):30-38. PubMed ID: 31433913
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Wnt/β-catenin by anthelmintic drug niclosamide effectively targets growth, survival, and angiogenesis of retinoblastoma.
Li Z; Li Q; Wang G; Huang Y; Mao X; Zhang Y; Wang X
Am J Transl Res; 2017; 9(8):3776-3786. PubMed ID: 28861168
[TBL] [Abstract][Full Text] [Related]
28. [Molecular mechanisms of niclosamide antitumor activity].
Moskaleva EY; Perevozchikova VG; Zhirnik AS; Severin SE
Biomed Khim; 2015; 61(6):680-93. PubMed ID: 26716739
[TBL] [Abstract][Full Text] [Related]
29. YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells.
Liu Z; Tao Z; Zhang Q; Wan S; Zhang F; Zhang Y; Wu G; Wang J
Cancer Chemother Pharmacol; 2018 Apr; 81(4):687-695. PubMed ID: 29392452
[TBL] [Abstract][Full Text] [Related]
30. Targeting Nanomedicines to Prostate Cancer: Evaluation of Specificity of Ligands to Two Different Receptors In Vivo.
Pearce AK; Fuchs AV; Fletcher NL; Thurecht KJ
Pharm Res; 2016 Oct; 33(10):2388-99. PubMed ID: 27225496
[TBL] [Abstract][Full Text] [Related]
31. The Sam-Sam interaction between Ship2 and the EphA2 receptor: design and analysis of peptide inhibitors.
Mercurio FA; Di Natale C; Pirone L; Iannitti R; Marasco D; Pedone EM; Palumbo R; Leone M
Sci Rep; 2017 Dec; 7(1):17474. PubMed ID: 29234063
[TBL] [Abstract][Full Text] [Related]
32. PET-Guided Evaluation and Optimization of Internalized Antibody-Drug Conjugates Targeting Erythropoietin-Producing Hepatoma A2 Receptor.
Jacobson O; Li Q; Chen H; Niu G; Kiesewetter DO; Xu L; Cook K; Yang G; Dall'Acqua W; Tsui P; Peng L; Chen X
J Nucl Med; 2017 Nov; 58(11):1838-1844. PubMed ID: 28546337
[TBL] [Abstract][Full Text] [Related]
33. The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.
Youngblood VM; Kim LC; Edwards DN; Hwang Y; Santapuram PR; Stirdivant SM; Lu P; Ye F; Brantley-Sieders DM; Chen J
Cancer Res; 2016 Apr; 76(7):1825-36. PubMed ID: 26833123
[TBL] [Abstract][Full Text] [Related]
34. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
35. New insights into niclosamide action: autophagy activation in colorectal cancer.
Newton PT
Biochem J; 2019 Mar; 476(5):779-781. PubMed ID: 30842311
[TBL] [Abstract][Full Text] [Related]
36. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Wang LH; Xu M; Fu LQ; Chen XY; Yang F
Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
[TBL] [Abstract][Full Text] [Related]
37. Niclosamide loaded biodegradable chitosan nanocargoes: an
Naqvi S; Mohiyuddin S; Gopinath P
R Soc Open Sci; 2017 Nov; 4(11):170611. PubMed ID: 29291056
[TBL] [Abstract][Full Text] [Related]
38. Preparation and antitumor evaluation of self-assembling oleanolic acid-loaded Pluronic P105/d-α-tocopheryl polyethylene glycol succinate mixed micelles for non-small-cell lung cancer treatment.
Wu H; Zhong Q; Zhong R; Huang H; Xia Z; Ke Z; Zhang Z; Song J; Jia X
Int J Nanomedicine; 2016; 11():6337-6352. PubMed ID: 27932881
[TBL] [Abstract][Full Text] [Related]
39. An ephrin mimetic peptide that selectively targets the EphA2 receptor.
Koolpe M; Dail M; Pasquale EB
J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647
[TBL] [Abstract][Full Text] [Related]
40. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
